Morning Trading May 29, page-12

  1. 91 Posts.
    BIO - Biome expects FY24 international sales revenue to grow 85%+ vs PCP (FY23 $459k)

    COV - Cleo's Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

    PER - PHASE IIB STUDY OF ATL1102 IN DMD COMPLETES RECRUITMENT

    GTG - Launches Revolutionary geneType Test covering 100% Risk of Breast andOvarian Cancer
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.